Latent TB Testing Market to Reach USD 773.4 Million by 2029, Driven by Advancements in Diagnostic Technologies

The latent TB testing market is projected to grow to USD 773.4 million by 2029 from USD 582.5 million in 2024, at a CAGR of 5.8% during the forecast period.
The global latent tuberculosis (TB) testing market [https://www.marketsandmarkets.com/Market-Reports/latent-tb-testing-market-125200332.html] is projected to grow from USD 582.5 million in 2024 to USD 773.4 million by 2029, reflecting a compound annual growth rate (CAGR) of 5.8%. This growth is fueled by the increasing global prevalence of tuberculosis, the rising demand for early detection, and the expansion of preventive healthcare initiatives.

Traditional tuberculin skin tests (TSTs) face challenges such as false positives, particularly in populations vaccinated with Bacillus Calmette-Guerin (BCG). This limitation has accelerated the adoption of more precise diagnostic methods, particularly interferon-gamma release assays (IGRAs). Additionally, global TB elimination programs led by governments and public health organizations are intensifying demand for efficient latent TB testing solutions. Greater awareness among healthcare providers and at-risk populations, including immunocompromised individuals such as those living with HIV, is further driving the market. Increased financial and regulatory support is also making advanced diagnostics more widely accessible, contributing to sustained market expansion.

Download PDF Brochure: Click Here [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=125200332]

Market Growth Fueled by IGRA Advancements

The latent TB testing market is undergoing a significant transformation with the growing emphasis on IGRA technology. These tests offer superior accuracy and sensitivity compared to TSTs, particularly in BCG-vaccinated individuals. As global healthcare systems move towards precision diagnostics, the demand for IGRAs is increasing due to their enhanced specificity and the ability to deliver results in a single visit. Furthermore, automation and technological advancements in IGRA platforms are making these tests more scalable and accessible, particularly in high-burden and resource-limited regions. This technological shift is expected to drive market growth, encouraging new entrants and further investments in IGRA innovations.

Market Segmentation Insights

By test type, the latent TB testing market is segmented into tuberculin skin tests (TSTs) and interferon-gamma release assays (IGRAs). The IGRA segment is projected to witness the highest growth, driven by its greater accuracy, reduced incidence of false positives, and improved patient convenience by eliminating the need for follow-up visits. These advantages are particularly crucial in high-risk populations and high-burden regions, further boosting IGRA adoption.

By application, the market is categorized into household contacts with pulmonary TB, people living with HIV, and other applications. The fastest-growing segment is expected to be household contacts with pulmonary TB. Individuals in close proximity to active TB patients are at heightened risk of infection, making routine screening a priority for TB control programs. Government and international health organizations are increasingly investing in the screening and management of latent TB in high-risk groups, with advanced diagnostics such as IGRAs playing a critical role in detecting and preventing disease progression.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=125200332 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=125200332&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=latenttbtestingmarket]

Key Market Players and Strategic Developments

The latent TB testing market features key players implementing diverse growth strategies, including product innovation, partnerships, expansions, and acquisitions, to strengthen their market position. Major companies include:

*
QIAGEN (Netherlands): A leading innovator in sample technologies, QIAGEN focuses on genomic and viral nucleic acid isolation, sequencing applications, and diagnostic test development. With a strong global presence and a dynamic R&D strategy, QIAGEN continues to expand its reach. In February 2023, its QuantiFERON-TB Gold Plus test received CE marking under the European Union's IVDR regulation, reinforcing its leadership in the market.

*
Revvity (US): A prominent player in health science solutions, Revvity specializes in multi-omics technologies, biomarker identification, and diagnostic innovations. With a robust distribution network spanning North America, Europe, and Asia Pacific, the company emphasizes organic growth, strategic investments, and R&D advancements to maintain its competitive edge.

*
Beijing Wantai Biopharmaceutical Co., Ltd. (China): A leader in infectious disease diagnostics, Wantai Biopharmaceutical focuses on ELISA, rapid tests, PCR, and chemiluminescence assays. Strong R&D capabilities and national research initiatives support the company's leadership position in the latent TB testing market.

Other notable market players include Sanofi (France), Endo, Inc. (US), bioMerieux (France), SD Biosensor, Inc. (South Korea), Lionex GmbH (Germany), Serum Institute of India Pvt. Ltd. (India), ARKRAY, Inc. (Japan), Zhi Fei Biological (China), AID Autoimmun Diagnostika GmbH (Germany), Boditech Med Inc. (South Korea), Bioneovan Co., Ltd (China), and Biopanda Reagents Ltd (UK).

With growing investments in advanced diagnostic solutions, increased funding for TB control programs, and heightened global awareness, the latent TB testing market is poised for steady expansion in the coming years.

For more information, Inquire Now! [https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=125200332&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=latenttbtestingmarket]

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=latent-tb-testing-market-to-reach-usd-7734-million-by-2029-driven-by-advancements-in-diagnostic-technologies]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/latent-tb-testing-market-125200332.html

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.